Cutaneous side-effects of kinase inhibitors and blocking antibodies
Caroline Robert, Jean‐Charles Soria, Alan Spatz et al. · The Lancet Oncology · 2005
Cited by 554 works. doi:10.1016/s1470-2045(05)70243-6
Authors
- Caroline Robert
- Jean‐Charles Soria
- Alan Spatz
- Axel Le Cesne
- David Malka
- Patricia Pautier
- Janine Wechsler
- C. Lhommé
- Bernard J. Escudier
- Valérie Boige
- Jean‐Pierre Armand
- Thierry Le Chevalier
References
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
- Strain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor